Inhibition of matrix metalloproteinases to reduce blood brain barrier disruption and haemorrhagic transformation in ischaemic stroke: go broad or go narrow?

Ischaemic stroke characterises impulsive cerebral-region hypoxia due to deep intracerebral arteriole blockage, often accompanied by permanent cerebral infarction and cognitive impairment. Thrombolysis with recombinant tissue plasminogen activator (rtPA) and thrombectomy remain the only guidance-approved therapies. However, emerging data draws clear links between such therapies and haemorrhage transformation, which occur when cerebral vasculature is damaged during ischaemia/reperfusion. Studies have shown that matrix metalloproteinases (MMPs) play a significant role in haemorrhage transformation, by depleting the extracellular matrix (ECM) and disrupting the blood brain barrier (BBB). Inhibitors of MMPs may be used to prevent ischaemic stroke patients from BBB disruption and haemorrhage transformation, particularly for those receiving rtPA treatment. Preclinical studies found that inhibition of MMPs with agents or in knock out mice, effectively reduced BBB disruption and infarct volume, leading to improved ischaemic stroke outcomes. At present, MMP inhibition is not an approved therapy for stroke patients. There remain concerns about timing, dosing, duration of MMP inhibition and selection of either broad spectrum or specific MMP inhibitors for stroke patients. This review aims to summarize current knowledge on MMP inhibition in ischaemic stroke and explore whether a broad spectrum or a specific MMP inhibitor should be used for ischaemic stroke patient treatment. It is crucial to inhibit MMP activities early and sufficiently to ensure BBB intact during ischaemia and reperfusion, but also to reduce side effects of MMP inhibitors to minimum. Recent advance in stroke therapy by thrombectomy could aid in such treatment with intra-arterially delivery of MMP inhibitors (and/or antioxidants).

• Publication year

  2024

• Venue

  Neuropharmacology

• Publication date

  2024-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.neuropharm.2024.110192PMID 39419277
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Matrix metalloproteinases at a glance.

  2024cited by this paper
• The Janus face of HIF-1α in ischemic stroke and the possible associated pathways.

  2024cited by this paper
• LOX-1 and MMP-9 inhibition attenuates the detrimental effects of delayed rt-PA therapy and improves outcomes after acute ischemic stroke

  2023cited by this paper
• Ischemic Tolerance—A Way to Reduce the Extent of Ischemia–Reperfusion Damage

  2023cited by this paper
• The efficacy and safety of alteplase treatment in patients with acute ischemic stroke with unknown time of onset: -Real world data.

  2023cited by this paper
• Angiogenesis after ischemic stroke

  2023cited by this paper
• An MMP-9 exclusive neutralizing antibody attenuates blood-brain barrier breakdown in mice with stroke and stroke patient-derived MMP-9 activity.

  2023cited by this paper
• The Role of Matrix Metalloproteinases in Hemorrhagic Transformation in the Treatment of Stroke with Tissue Plasminogen Activator

  2023cited by this paper
• HIF-1, an important regulator in potential new therapeutic approaches to ischemic stroke.

  2023cited by this paper
• Cerebral edema after ischemic stroke: Pathophysiology and underlying mechanisms

  2022cited by this paper
• MMP-12 knockdown prevents secondary brain damage after ischemic stroke in mice.

  2022cited by this paper
• Therapeutic efficacy of matrix metalloproteinase-12 suppression on neurological recovery after ischemic stroke: Optimal treatment timing and duration

  2022cited by this paper
• An Unexplored Role for MMP-7 (Matrix Metalloproteinase-7) in Promoting Gut Permeability After Ischemic Stroke

  2022cited by this paper
• Matrix Metalloproteinases: From Molecular Mechanisms to Physiology, Pathophysiology, and Pharmacology

  2022cited by this paper
• Teriparatide induces angiogenesis in ischemic cerebral infarction zones of rats through AC/PKA signaling and reduces ischemia-reperfusion injury.

  2022cited by this paper
• Post-stroke Impairment of the Blood–Brain Barrier and Perifocal Vasogenic Edema Is Alleviated by Endovascular Mesenchymal Stem Cell Administration: Modulation of the PKCδ/MMP9/AQP4-Mediated Pathway

  2022cited by this paper
• World Stroke Organization (WSO): Global Stroke Fact Sheet 2022

  2022cited by this paper
• Association of Initial Potassium Levels with the Type of Stroke in the Emergency Department.

  2021cited by this paper
• Causal Effect of MMP-1 (Matrix Metalloproteinase-1), MMP-8, and MMP-12 Levels on Ischemic Stroke

  2021cited by this paper
• The association of matrix metalloproteinase 9 (MMP9) with hippocampal volume in schizophrenia: a preliminary MRI study

  2021cited by this paper
• Matrix Metalloproteinase-9 Expression is Enhanced by Ischemia and Tissue Plasminogen Activator and Induces Hemorrhage, Disability and Mortality in Experimental Stroke.

  2021cited by this paper
• Efficacy and Safety of Intravenous rtPA in Ischemic Strokes Due to Small-Vessel Occlusion: Systematic Review and Meta-Analysis

  2021cited by this paper
• Biological Functions and Regulatory Mechanisms of Hypoxia-Inducible Factor-1α in Ischemic Stroke

  2021cited by this paper
• MMPs and TIMPs levels are correlated with anthropometric parameters, blood pressure, and endothelial function in obesity

  2021cited by this paper
• Hemorrhagic Transformation in Ischemic Stroke and the Role of Inflammation

  2021cited by this paper
• Induced mRNA expression of matrix metalloproteinases Mmp-3, Mmp-12, and Mmp-13 in the infarct cerebral cortex of photothrombosis model mice.

  2020cited by this paper
• Structure and Function of Human Matrix Metalloproteinases

  2020cited by this paper
• The Roles of Matrix Metalloproteinases and Their Inhibitors in Human Diseases

  2020cited by this paper
• The Stroke-Induced Blood-Brain Barrier Disruption: Current Progress of Inspection Technique, Mechanism, and Therapeutic Target

  2020cited by this paper
• Mechanisms in blood-brain barrier opening and metabolism-challenged cerebrovascular ischemia with emphasis on ischemic stroke

  2020cited by this paper
• Up-regulation of brain cytokines and metalloproteinases 1 and 2 contributes to neurological deficit and brain damage in transient ischemic stroke.

  2019cited by this paper
• The Rebirth of Matrix Metalloproteinase Inhibitors: Moving Beyond the Dogma

  2019cited by this paper
• The past, present and future perspectives of matrix metalloproteinase inhibitors.

  2019cited by this paper
• Ischaemic stroke

  2019cited by this paper
• Novel Drug Targets for Ischemic Stroke Identified Through Mendelian Randomization Analysis of the Blood Proteome.

  2019cited by this paper
• Neuroinflammatory mechanisms of blood-brain barrier damage in ischemic stroke.

  2019cited by this paper
• Current progress in searching for clinically useful biomarkers of blood–brain barrier damage following cerebral ischemia

  2018cited by this paper
• Reactive Oxygen Species Formation in the Brain at Different Oxygen Levels: The Role of Hypoxia Inducible Factors

  2018cited by this paper
• MMP10 Promotes Efficient Thrombolysis After Ischemic Stroke in Mice with Induced Diabetes

  2018cited by this paper
• Serum matrix metalloproteinase-8, tissue inhibitor of metalloproteinase and myeloperoxidase in ischemic stroke.

  2018cited by this paper
• Matrix Metalloproteinase Inhibitors in Cancer Therapy: Turning Past Failures Into Future Successes

  2018cited by this paper
• Efficacy of Minocycline in Acute Ischemic Stroke: A Systematic Review and Meta-Analysis of Rodent and Clinical Studies

  2018cited by this paper
• Selective small-molecule inhibitors as chemical tools to define the roles of matrix metalloproteinases in disease.

  2017cited by this paper
• Discovery of a highly selective chemical inhibitor of matrix metalloproteinase-9 (MMP-9) that allosterically inhibits zymogen activation

  2017cited by this paper
• Blood-brain barrier dysfunction and recovery after ischemic stroke.

  2017cited by this paper
• Disrupted Ionic Homeostasis in Ischemic Stroke and New Therapeutic Targets.

  2017cited by this paper
• Implications of MMP9 for Blood Brain Barrier Disruption and Hemorrhagic Transformation Following Ischemic Stroke

  2016cited by this paper
• Matrix metalloproteinase-13 participates in neuroprotection and neurorepair after cerebral ischemia in mice.

  2016cited by this paper
• MMP‐9 in translation: from molecule to brain physiology, pathology, and therapy

  2016cited by this paper
• Matrix Metalloprotease 3 Exacerbates Hemorrhagic Transformation and Worsens Functional Outcomes in Hyperglycemic Stroke

  2016cited by this paper
• Perturbations of the cerebrovascular matrisome: A convergent mechanism in small vessel disease of the brain?

  2016cited by this paper
• Matrix metalloproteinases in the brain and blood–brain barrier: Versatile breakers and makers

  2016cited by this paper
• Post-transcriptional inactivation of matrix metalloproteinase-12 after focal cerebral ischemia attenuates brain damage

  2015cited by this paper
• Matrix Metalloproteinase-12 Induces Blood–Brain Barrier Damage After Focal Cerebral Ischemia

  2015cited by this paper
• Hypoxia-Inducible Factor as an Angiogenic Master Switch

  2015cited by this paper
• Role of P38 MAPK on MMP Activity in Photothrombotic Stroke Mice as Measured using an Ultrafast MMP Activatable Probe

  2015cited by this paper
• Treatment with recombinant tissue plasminogen activator (r-TPA) induces neutrophil degranulation in vitro via defined pathways.

  2015cited by this paper
• Matrix metalloproteinases as therapeutic targets for stroke.

  2015cited by this paper
• Matrix metalloproteinases in inflammation.

  2014cited by this paper
• The significance of matrix metalloproteinase (MMP)-2 and MMP-9 in the ischemic stroke

  2014cited by this paper
• Is there new hope for therapeutic matrix metalloproteinase inhibition?

  2014cited by this paper
• Impact of the neutrophil response to granulocyte colony-stimulating factor on the risk of hemorrhage when used in combination with tissue plasminogen activator during the acute phase of experimental stroke

  2014cited by this paper
• Stepwise recruitment of transcellular and paracellular pathways underlies blood-brain barrier breakdown in stroke.

  2014cited by this paper
• Matrix Metalloproteinase-8 is a Novel Pathogenetic Factor in Focal Cerebral Ischemia

  2014cited by this paper
• Astrocyte mediated MMP-9 activation in the synapse dysfunction: An implication in Alzheimer disease.

  2014cited by this paper
• Hypoxia Selectively Disrupts Brain Microvascular Endothelial Tight Junction Complexes Through a Hypoxia‐Inducible Factor‐1 (HIF‐1) Dependent Mechanism

  2014cited by this paper
• Effects of edaravone, a free radical scavenger, on circulating levels of MMP-9 and hemorrhagic transformation in patients with intravenous thrombolysis using low-dose alteplase.

  2014cited by this paper
• Hemorrhagic Transformation after Ischemic Stroke in Animals and Humans

  2014cited by this paper
• Hemorrhagic Transformation: A Review of the Rate of Hemorrhage in the Major Clinical Trials of Acute Ischemic Stroke

  2013cited by this paper
• Hemorrhagic transformation in acute ischemic stroke

  2013cited by this paper
• MMP9 Variation After Thrombolysis Is Associated With Hemorrhagic Transformation of Lesion and Death

  2013cited by this paper
• Early Inhibition of MMP Activity in Ischemic Rat Brain Promotes Expression of Tight Junction Proteins and Angiogenesis During Recovery

  2013cited by this paper
• Matrix Metalloproteinases and Blood-Brain Barrier Disruption in Acute Ischemic Stroke

  2013cited by this paper
• proMetalloproteinase‐10 is associated with brain damage and clinical outcome in acute ischemic stroke

  2013cited by this paper
• MMP9: a novel function in synaptic plasticity.

  2012cited by this paper
• The tissue inhibitors of metalloproteinases (TIMPs): an ancient family with structural and functional diversity.

  2010cited by this paper
• Matrix Metalloproteinase-9 Mediates Hypoxia-Induced Vascular Leakage in the Brain via Tight Junction Rearrangement

  2010cited by this paper
• Genome-Wide Association Scan Identifies Variants near Matrix Metalloproteinase (MMP) Genes on Chromosome 11q21–22 Strongly Associated With Serum MMP-1 Levels

  2009cited by this paper
• Tissue-type plasminogen activator (t-PA) induces stromelysin-1 (MMP-3) in endothelial cells through activation of lipoprotein receptor-related protein.

  2009cited by this paper
• Early inhibition of HIF-1alpha with small interfering RNA reduces ischemic-reperfused brain injury in rats.

  2009cited by this paper
• Microglial Low-Density Lipoprotein Receptor-Related Protein 1 Mediates the Effect of Tissue-Type Plasminogen Activator on Matrix Metalloproteinase-9 Activity in the Ischemic Brain

  2009cited by this paper
• MMPs as therapeutic targets--still a viable option?

  2008cited by this paper
• Tissue plasminogen activator (t‐PA) promotes neutrophil degranulation and MMP‐9 release

  2008cited by this paper
• Nitric oxide regulation of MMP-9 activation and its relationship to modifications of the cysteine switch.

  2008cited by this paper
• MMP-9–Positive Neutrophil Infiltration Is Associated to Blood–Brain Barrier Breakdown and Basal Lamina Type IV Collagen Degradation During Hemorrhagic Transformation After Human Ischemic Stroke

  2008cited by this paper
• A microarray study of gene and protein regulation in human and rat brain following middle cerebral artery occlusion

  2007cited by this paper
• Neuron-Specific Inactivation of the Hypoxia Inducible Factor 1α Increases Brain Injury in a Mouse Model of Transient Focal Cerebral Ischemia

  2007cited by this paper
• Neurovascular Proteases in Brain Injury, Hemorrhage and Remodeling After Stroke

  2007cited by this paper
• Matrix Metalloproteinase-Mediated Disruption of Tight Junction Proteins in Cerebral Vessels is Reversed by Synthetic Matrix Metalloproteinase Inhibitor in Focal Ischemia in Rat

  2007cited by this paper
• Stromelysin‐1 (MMP‐3) is critical for intracranial bleeding after t‐PA treatment of stroke in mice

  2007cited by this paper
• Tissue-type Plasminogen Activator Acts as a Cytokine That Triggers Intracellular Signal Transduction and Induces Matrix Metalloproteinase-9 Gene Expression*

  2006cited by this paper
• Individual Timp Deficiencies Differentially Impact Pro-MMP-2 Activation*

  2006cited by this paper
• New-onset hypertension and inflammatory response/poor outcome in acute ischemic stroke

  2006cited by this paper
• Role of matrix metalloproteinases in delayed cortical responses after stroke

  2006cited by this paper
• Blood-brain barrier disruption by stromelysin-1 facilitates neutrophil infiltration in neuroinflammation.

  2006cited by this paper
• Association between tPA therapy and raised early matrix metalloproteinase-9 in acute stroke

  2006cited by this paper
• Gene Expression in Blood Changes Rapidly in Neutrophils and Monocytes after Ischemic Stroke in Humans: A Microarray Study

  2006cited by this paper
• A Highly Specific Inhibitor of Matrix Metalloproteinase-9 Rescues Laminin from Proteolysis and Neurons from Apoptosis in Transient Focal Cerebral Ischemia

  2005cited by this paper
• Free radicals as triggers of brain edema formation after stroke.

  2005cited by this paper
• NF-κB and AP-1 Connection: Mechanism of NF-κB-Dependent Regulation of AP-1 Activity

  2004cited by this paper

• BMSC-Derived Exosomal miR-21a-5p Ameliorates Blood–Brain Barrier Injury and Hemorrhagic Transformation

  2026cites this paper
• Secondary demyelination after stroke: glial cell crosstalk

  2026cites this paper
• Impact of Aging, Sex, and Species on the mRNA Expression of Matrix Metalloproteinases Following Ischemic Stroke

  2026cites this paper
• Chronic inflammation linking atherosclerosis to cognitive impairment: Multi-target mechanisms and therapeutic advances in chinese herbal medicine

  2025cites this paper
• Voclosporin promotes neurological function recovery by inhibiting inflammation and maintaining blood–brain barrier integrity following rtPA reperfusion after MCAO in mice

  2025cites this paper
• Discovery and Characterisation of Novel Poly-Histidine-Poly-Glycine Peptides as Matrix Metalloproteinase Inhibitors

  2025cites this paper
• Beyond Reperfusion: Adjunctive Therapies Targeting Inflammation, Edema, and Blood-Brain Barrier Dysfunction in Ischemic Stroke

  2025influential citation
• Neuroglia and immune cells play different roles in neuroinflammation and neuroimmune response in post-stroke neural injury and repair

  2025cites this paper
• Hypoxic Neuroinflammation in the Pathogenesis of Multiple Sclerosis

  2025cites this paper
• Innovation and development of stent retrievers in acute ischemic stroke

  2025cites this paper
• The impact of low plasma atherosclerosis index on hemorrhagic transformation after endovascular treatment of large artery atherosclerotic stroke

  2025cites this paper
• Forced and voluntary exercise exert differential neuroprotective effects in cerebral ischemia-reperfusion injury by inhibiting neutrophil infiltration and blood-brain barrier disruption.

  2025cites this paper
• Immune-mediated blood-brain barrier disruption after ischemic stroke: mechanisms and therapeutic targets

  2025cites this paper
• Neuroprotective Effects of Bromelain on Acute Ischemic Stroke in Rats

  2025cites this paper
• Circulating cfdna: A novel biomarker for preventing early recurrence in ischemic stroke.

  2025cites this paper
• TEAD1 knockdown impedes the inflammation and ferroptosis by mediating MMP3 in cerebral ischemia reperfusion.

  2025cites this paper
• Imaging probes for the detection of brain microenvironment.

  2025cites this paper